July 24, 2024 – Page 14 – Goldea Capital

Fidelity D & D Bancorp, Inc. Reports Second Quarter 2024 Financial Results

Written by Customer Service on July 24, 2024. Posted in Public Companies.

DUNMORE, Pa., July 24, 2024 (GLOBE NEWSWIRE) — Fidelity D & D Bancorp, Inc. (NASDAQ: FDBC) and its banking subsidiary, The Fidelity Deposit and Discount Bank, announced its unaudited, consolidated financial results for the three and six-month periods ended June 30, 2024. Unaudited Financial Information Net income for the quarter ended June 30, 2024 was $4.9 million, or $0.86 diluted earnings per share, compared to $5.4 million, or $0.94 diluted earnings per share, for the quarter ended June 30, 2023. The $0.5 million decline in net income resulted primarily from the $0.4 million decrease in net interest income led by higher interest expense. The increase of $0.2 million in non-interest expenses and $0.2 million higher provision for credit losses on unfunded loan commitments was offset by the $0.4 million reduction in the provision...

OTC Markets Group Announces Real-Time Data Distribution with uSMART Securities Out of Hong Kong

Written by Customer Service on July 24, 2024. Posted in Public Companies.

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated financial markets for over 12,000 U.S. and global securities, today announced new data distribution capabilities in collaboration with uSMART Securities, an advanced financial trading platform for global investors. uSMART Securities, a leading fintech brokerage firm based in Hong Kong, is now a distributor for OTC Markets Group’s L1 and L2 real-time data and with the data being available in their mobile app for participating users. uSMART operates a financial trading platform that provides real-time stock quotes, stock trading strategies for investors, and 24-hour account service. With this new integration, OTC Markets Group expands their Asian market presence and deepens their technology bench with an additional partner in Hong...

Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal

Written by Customer Service on July 24, 2024. Posted in Public Companies.

Tilray’s Solução Oral THC10:CBD10 Medical Cannabis Extract is Now Approved for Medical Use in Portugal CANTANHEDE, Portugal, July 24, 2024 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced another milestone achievement in medical cannabis in Europe. Following the successful approval of Tilray Medical whole flower THC 18, and approval for the first cannabis extract in Portugal earlier this year, Tilray Medical receives its second approval for a new medical cannabis extract in Portugal: Tilray Oral Solution THC10:CBD10, also known as Tilray Solução Oral THC10:CBD10. Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, Inc., said, “We are proud to have received approval...

Stifel Reports Second Quarter 2024 Results

Written by Customer Service on July 24, 2024. Posted in Public Companies.

ST. LOUIS, July 24, 2024 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today reported net revenues of $1.2 billion for the three months ended June 30, 2024, compared with $1.1 billion a year ago. Net income available to common shareholders was $156.0 million, or $1.41 per diluted common share, compared with $125.0 million, or $1.10 per diluted common share for the second quarter of 2023. Non-GAAP net income available to common shareholders was $176.6 million, or $1.60 per diluted common share for the second quarter of 2024. Ronald J. Kruszewski, Chairman and Chief Executive Officer, said “Stifel generated our second highest quarterly net revenue in company history, as each of our operating segments generated solid year-on-year gains. Stifel’s strong results reflect improved market conditions and illustrate the benefits of our...

Sylogist Announces Details of Second Quarter 2024 Earnings Conference Call and Update to Normal Course Issuer Bid

Written by Customer Service on July 24, 2024. Posted in Public Companies.

CALGARY, Alberta, July 24, 2024 (GLOBE NEWSWIRE) — Sylogist Ltd. (TSX: SYZ) (“Sylogist” or the “Company”), a leading public sector SaaS company, is pleased to announce that its financial statements for the second quarter of fiscal 2024 will be released before market open on August 8, 2024. The Company will host a conference call at 8:30 AM Eastern Time on August 8, 2024. Bill Wood, Sylogist’s President and Chief Executive Officer, and Sujeet Kini, Sylogist’s Chief Financial Officer, will review the Company’s recent financial results and business performance. Conference Call Details:Date: Thursday, August 8, 2024Time: 8:30 a.m. EDTParticipant Toll-Free Dial-In Number: + 1-844-763-8274 Webcast link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZCvzfxKV This conference call will be recorded and available for replay...

Talen Energy to Report Second Quarter 2024 Financial Results on August 13, 2024

Written by Customer Service on July 24, 2024. Posted in Public Companies.

HOUSTON, July 24, 2024 (GLOBE NEWSWIRE) — Talen Energy Corporation (“Talen”) (NASDAQ: TLN) plans to release its second quarter 2024 financial results on Tuesday, August 13, 2024, before market open. President and Chief Executive Officer Mac McFarland and Chief Financial Officer Terry Nutt will discuss the financial and operating results during an earnings call at 10:00 a.m. EDT (9:00 a.m. CDT) on August 13, 2024. To listen to the earnings call, please register in advance for the webcast. For participants joining the call via phone, please register here prior to the start time to receive dial-in information. For those unable to participate in the live event, a digital replay of the earnings call will be archived for approximately one year and available on Talen’s Investor Relations website at https://ir.talenenergy.com/news-events/events. About...

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Written by Customer Service on July 24, 2024. Posted in Public Companies.

Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the first patient has been dosed in the Company’s phase 3 trial evaluating the efficacy and safety of petosemtamab, a Biclonics® targeting EGFR and LGR5, compared to investigator’s choice of single agent chemotherapy or cetuximab in previously treated (2/3L) patients with recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) referred to as the LiGeR-HN2 trial. Merus has confirmed through feedback with...

Interpublic Announces Second Quarter and First Half 2024 Results

Written by Customer Service on July 24, 2024. Posted in Public Companies.

New York, NY, July 24, 2024 (GLOBE NEWSWIRE) — Total revenue including billable expenses was $2.71 billion Revenue before billable expenses (“net revenue”) was flat at $2.33 billion, with an organic increase of 1.7% Reported net income was $214.5 million Adjusted EBITA before restructuring charges was $338.9 million Margin of adjusted EBITA before restructuring charges was 14.6% on revenue before billable expenses Diluted earnings per share was $0.57 as reported and $0.61 as adjusted Philippe Krakowsky, CEO of IPG: “Second quarter performance was solid, with moderate acceleration in organic growth, as well as margin expansion compared to the same period last year. Consistent with our longer-term performance, IPG Mediabrands and IPG Health led the way in the quarter. We also saw notable contributions to growth from...

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

Written by Customer Service on July 24, 2024. Posted in Public Companies.

– Safety, tolerability, pharmacokinetic and pharmacodynamic profile of VG-3927 supports continued development as potential once-daily oral therapy for Alzheimer’s disease (AD) – – VG-3927 achieved robust decrease of sTREM2 in CSF demonstrating clinical proof-of-target engagement- – New preclinical and clinical data from SAD cohorts to be presented at upcoming 2024 Alzheimer’s Association International Conference (AAIC) – – Company plans to report complete Phase 1 data, including data from AD cohort, in Q1’2025 – WATERTOWN, Mass., July 24, 2024 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced interim data from its ongoing Phase...

Oatly Reports Second Quarter 2024 Financial Results

Written by Customer Service on July 24, 2024. Posted in Public Companies.

MALMÖ, Sweden, July 24, 2024 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world’s original and largest oat drink company, today announced financial results for the second quarter and six months ended June 30, 2024. Jean-Christophe Flatin, Oatly’s CEO, commented, “I am pleased to report another quarter of solid progress in strengthening our business. In the second quarter, we grew volumes in every segment, continued to structurally reduce our cost structure, and continued to invest to further strengthen our brand. Overall, we are making good progress on the three strategic pillars that we are focusing on in 2024: to bring the Oatly magic to more people, to continue our work on the calibration of resources, and to focus on execution.” Flatin added, “Given our solid performance through the first...

Day: July 24, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice